General Surgery-Anne Arundel Medical Center, Annapolis, MD.
Vascular Surgery-MedStar Health, Georgetown/Washington Hospital Center, Washington, DC.
Ann Vasc Surg. 2024 Feb;99:262-271. doi: 10.1016/j.avsg.2023.08.020. Epub 2023 Oct 4.
Our primary objective was to determine the relationship between plasma fibrinogen levels (PFLs) and major bleeding complications during catheter-directed thrombolysis, including final, nadir, and change over time. Furthermore, we sought to evaluate additional predictors of bleeding outcomes, including duration of lysis and total dose of tissue plasminogen activator received.
In this multicenter retrospective cohort study, we reviewed all patients undergoing catheter-directed thrombolysis between January 2016 and August 2021. Patients undergoing thrombolysis for management of peripheral arterial or venous thromboses, as well as for submassive pulmonary embolism, were included. We examined the relationships between PFLs during catheter-directed lysis and the incidence of major bleeding-that is significant hemorrhage requiring transfusion, intracranial hemorrhage, or hemorrhage requiring adjunctive procedures. We also examined the duration of lysis and total lytic agent dose received to assess for association with major bleeding.
A total of 438 patients underwent catheter-directed lysis from January 1, 2016 through August 21, 2021, with a major bleeding rate of 16%. Patients who experienced major bleeding were more likely to be older (P = 0.022), experience in-stent thrombosis (P = 0.041), or have thrombosis in a lower extremity vessel (P = 0.011). There was no association between the incidence of major bleeding and a nadir PFL of <150 mg/dL (P = 0.194). Those who experienced major bleeding complications had a significantly greater decrease in PFL from baseline to nadir. This was true for both absolute (P = 0.029) and relative (P = 0.034) PFL decrease. Only percent decrease remained a significant predictor when adjusting for age, thrombosis type, and thrombosis location (P = 0.041). The PFL changes that were the best predictors of major bleeding complications were an absolute decrease of 146 mg/dL, or a relative decrease of 47%, giving a sensitivity and specificity of 71% and 48%, respectively. If neither were true, the negative predictive value for major bleeding was 89% regardless of absolute PFL.
In this large, multicenter cohort, there does not appear to be an association between absolute PFL and major bleeding during catheter-directed lysis. Specifically, the typical absolute threshold of < 150 mg/dL was not an independent predictor of major bleeding. There was an association between percent-change in plasma fibrinogen and major bleeding, which aligns with the underlying physiologic mechanism of fibrinogen degradation coagulopathy. Applying a so-called "50-150 Rule" to catheter-directed lysis may decrease bleeding complications. That is, continued lysis should be re-evaluated if PFL drops by ≥150 mg/dL or by ≥50% from baseline regardless of absolute PFL.
我们的主要目标是确定血浆纤维蛋白原水平(PFLs)与导管定向溶栓过程中的主要出血并发症之间的关系,包括最终、最低和随时间的变化。此外,我们试图评估出血结局的其他预测因素,包括溶栓时间和接受的组织型纤溶酶原激活剂总剂量。
在这项多中心回顾性队列研究中,我们回顾了 2016 年 1 月至 2021 年 8 月期间接受导管定向溶栓的所有患者。包括接受溶栓治疗以治疗外周动脉或静脉血栓形成以及亚大面积肺栓塞的患者。我们检查了导管定向溶栓过程中 PFLs 与主要出血(即需要输血、颅内出血或需要辅助治疗的显著出血)发生率之间的关系。我们还检查了溶栓时间和总溶栓剂剂量,以评估与主要出血的关系。
共有 438 名患者于 2016 年 1 月 1 日至 2021 年 8 月 21 日接受了导管定向溶栓治疗,主要出血率为 16%。发生大出血的患者更有可能年龄较大(P=0.022),存在支架内血栓形成(P=0.041)或下肢血管血栓形成(P=0.011)。纤维蛋白原水平最低值<150mg/dL 与主要出血发生率之间无关联(P=0.194)。发生大出血并发症的患者从基线到最低值时 PFL 显著下降。无论是绝对(P=0.029)还是相对(P=0.034)纤维蛋白原下降,均如此。仅当调整年龄、血栓类型和血栓位置时,百分比下降仍然是主要出血并发症的显著预测因素(P=0.041)。对主要出血并发症的最佳预测纤维蛋白原变化是绝对值下降 146mg/dL,或相对下降 47%,灵敏度和特异性分别为 71%和 48%。如果两者都不成立,则无论绝对纤维蛋白原水平如何,主要出血的阴性预测值均为 89%。
在这项大型多中心队列研究中,导管定向溶栓过程中 PFL 绝对值与主要出血之间似乎没有关联。具体来说,<150mg/dL 的典型绝对阈值并不是主要出血的独立预测因素。纤维蛋白原血浆变化百分比与主要出血之间存在关联,这与纤维蛋白原降解性凝血病的潜在生理机制一致。在导管定向溶栓中应用所谓的“50-150 规则”可能会减少出血并发症。也就是说,如果纤维蛋白原水平下降≥150mg/dL 或从基线下降≥50%,无论绝对纤维蛋白原水平如何,都应重新评估溶栓治疗。